These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

71 related articles for article (PubMed ID: 2600802)

  • 1. Pharmacodynamic modeling of verapamil effects under steady-state and nonsteady-state conditions.
    Schwartz JB; Verotta D; Sheiner LB
    J Pharmacol Exp Ther; 1989 Dec; 251(3):1032-8. PubMed ID: 2600802
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Concentration/effect analysis of verapamil: evaluation of different approaches.
    Harder S; Rietbrock S; Thürmann P
    Int J Clin Pharmacol Ther Toxicol; 1993 Oct; 31(10):469-75. PubMed ID: 8262684
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Stereoselective verapamil disposition and dynamics in aging during racemic verapamil administration.
    Abernethy DR; Wainer IW; Longstreth JA; Andrawis NS
    J Pharmacol Exp Ther; 1993 Aug; 266(2):904-11. PubMed ID: 8355215
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Verapamil pharmacodynamics and disposition in obese hypertensive patients.
    Abernethy DR; Schwartz JB
    J Cardiovasc Pharmacol; 1988 Feb; 11(2):209-15. PubMed ID: 2452316
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Insulin detemir under steady-state conditions: no accumulation and constant metabolic effect over time with twice daily administration in subjects with Type 1 diabetes.
    Bott S; Tusek C; Jacobsen LV; Endahl L; Draeger E; Kapitza C; Heise T
    Diabet Med; 2006 May; 23(5):522-8. PubMed ID: 16681561
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Concentration/effect relationship and enantioselective analysis of verapamil in hypertensive patients.
    Harder S; Thürmann P; Siewert M; Blume H; Rietbrock N; vander Kleijn J; Gierend M
    J Cardiovasc Pharmacol; 1992 May; 19(5):665-9. PubMed ID: 1381762
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetic-pharmacodynamic modeling of mivacurium in rats.
    Trocóniz IF; Garrido MJ; García E; Suárez E; Calvo R
    J Pharm Sci; 1997 Feb; 86(2):252-6. PubMed ID: 9040105
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Basic concepts of pharmacokinetic/pharmacodynamic (PK/PD) modelling.
    Meibohm B; Derendorf H
    Int J Clin Pharmacol Ther; 1997 Oct; 35(10):401-13. PubMed ID: 9352388
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Automated responsiveness monitor to titrate propofol sedation.
    Doufas AG; Morioka N; Mahgoub AN; Bjorksten AR; Shafer SL; Sessler DI
    Anesth Analg; 2009 Sep; 109(3):778-86. PubMed ID: 19690246
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics and dynamics of (+/-)-verapamil in lean and obese Zucker rats.
    Todd EL; Abernethy DR
    J Pharmacol Exp Ther; 1986 Aug; 238(2):642-7. PubMed ID: 3735134
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of grapefruit juice and smoking on verapamil concentrations in steady state.
    Fuhr U; Müller-Peltzer H; Kern R; Lopez-Rojas P; Jünemann M; Harder S; Staib AH
    Eur J Clin Pharmacol; 2002 Apr; 58(1):45-53. PubMed ID: 11956673
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetic-pharmacodynamic modelling of the EEG effect of alfentanil in rats: assessment of rapid functional adaptation.
    Cox EH; Kuipers JA; Danhof M
    Br J Pharmacol; 1998 Aug; 124(7):1534-40. PubMed ID: 9723968
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Concentration/effect analysis of antihypertensive drugs: single dose and steady state response to verapamil.
    Harder S; Thürmann P
    Int J Clin Pharmacol Ther Toxicol; 1992 Nov; 30(11):507. PubMed ID: 1490810
    [No Abstract]   [Full Text] [Related]  

  • 14. Steady-state pharmacokinetics and pharmacodynamics in methadone maintenance patients: comparison of those who do and do not experience withdrawal and concentration-effect relationships.
    Dyer KR; Foster DJ; White JM; Somogyi AA; Menelaou A; Bochner F
    Clin Pharmacol Ther; 1999 Jun; 65(6):685-94. PubMed ID: 10391674
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relationship between depth of anesthesia and effect-site concentration of propofol during induction with the target-controlled infusion technique in elderly patients.
    Liu SH; Wei W; Ding GN; Ke JD; Hong FX; Tian M
    Chin Med J (Engl); 2009 Apr; 122(8):935-40. PubMed ID: 19493418
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacodynamics of controlled release verapamil in patients with hypertension: an analysis using spline functions.
    Aarons L; Baxter C; Gupta S
    Biopharm Drug Dispos; 2004 Jul; 25(5):219-25. PubMed ID: 15248191
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of infusion rate on thiopental dose-response relationships. Assessment of a pharmacokinetic-pharmacodynamic model.
    Gentry WB; Krejcie TC; Henthorn TK; Shanks CA; Howard KA; Gupta DK; Avram MJ
    Anesthesiology; 1994 Aug; 81(2):316-24; discussion 25A. PubMed ID: 8053580
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of calcium to reverse the electrocardiographic effects of hyperkalemia in the isolated rat heart: a prospective, dose-response study.
    Bisogno JL; Langley A; Von Dreele MM
    Crit Care Med; 1994 Apr; 22(4):697-704. PubMed ID: 8143480
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Haemodynamic dose-response effects of i.v. verapamil in coronary artery disease.
    Silke B; Verma SP; Ahuja RC; Nelson GI; Hussain M; Taylor SH
    Herz; 1984 Dec; 9(6):353-61. PubMed ID: 6510876
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of hydrocortisone on phenylephrine--mean arterial pressure dose-response relationship in septic shock.
    Bellissant E; Annane D
    Clin Pharmacol Ther; 2000 Sep; 68(3):293-303. PubMed ID: 11014411
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.